Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 10175
TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518497BDBM518497(US11124509, Compound 68)
Affinity DataIC50: 1.20nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518501BDBM518501(US11124509, Compound 69)
Affinity DataIC50: 3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518482BDBM518482(US11124509, Compound 55)
Affinity DataIC50: 4.71nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518465BDBM518465(US11124509, Compound 37)
Affinity DataIC50: 5.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518474BDBM518474(US11124509, Compound 46)
Affinity DataIC50: 5.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518475BDBM518475(US11124509, Compound 47)
Affinity DataIC50: 6.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518472BDBM518472(US11124509, Compound 44)
Affinity DataIC50: 6.66nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518488BDBM518488(US11124509, Compound 61)
Affinity DataIC50: 7.55nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518481BDBM518481(US11124509, Compound 54)
Affinity DataIC50: 31.2nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518469BDBM518469(US11124509, Compound 41)
Affinity DataIC50: 33nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518483BDBM518483(US11124509, Compound 56)
Affinity DataIC50: 43.6nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518491BDBM518491(US11124509, Compound 64)
Affinity DataIC50: 44.6nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518489BDBM518489(US11124509, Compound 62)
Affinity DataIC50: 45.8nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518492BDBM518492(US11124509, Compound 65)
Affinity DataIC50: 46.2nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518467BDBM518467(US11124509, Compound 39)
Affinity DataIC50: 46.4nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518462BDBM518462(US11124509, Compound 34)
Affinity DataIC50: 49nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518496BDBM518496(US11124509, Compound 67)
Affinity DataIC50: 50nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518487BDBM518487(US11124509, Compound 60)
Affinity DataIC50: 71.7nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518485BDBM518485(US11124509, Compound 58)
Affinity DataIC50: 78nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518466BDBM518466(US11124509, Compound 38)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518468BDBM518468(US11124509, Compound 40)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518453BDBM518453(US11124509, Compound 20)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518471BDBM518471(US11124509, Compound 43)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518454BDBM518454(US11124509, Compound 22)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518473BDBM518473(US11124509, Compound 45)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518456BDBM518456(US11124509, Compound 26)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518457BDBM518457(US11124509, Compound 27)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518458BDBM518458(US11124509, Compound 28)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518476BDBM518476(US11124509, Compound 48)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518459BDBM518459(US11124509, Compound 29)
Affinity DataIC50: 100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518463BDBM518463(US11124509, Compound 36)
Affinity DataIC50: 103nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518484BDBM518484(US11124509, Compound 57)
Affinity DataIC50: 128nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518478BDBM518478(US11124509, Compound 50)
Affinity DataIC50: 138nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518455BDBM518455(US11124509, Compound 24)
Affinity DataIC50: 200nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518461BDBM518461(US11124509, Compound 33)
Affinity DataIC50: 200nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518479BDBM518479(US11124509, Compound 51)
Affinity DataIC50: 260nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518450BDBM518450(US11124509, Compound 10)
Affinity DataIC50: 264nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518495BDBM518495(US11124509, Compound 66)
Affinity DataIC50: 285nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518448BDBM518448(US11124509, Compound 6)
Affinity DataIC50: 354nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518490BDBM518490(US11124509, Compound 63)
Affinity DataIC50: 399nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518449BDBM518449(US11124509, Compound 8)
Affinity DataIC50: 811nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518486BDBM518486(US11124509, Compound 59)
Affinity DataIC50: 889nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518480BDBM518480(US11124509, Compound 53)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518451BDBM518451(US11124509, Compound 16)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518452BDBM518452(US11124509, Compound 17)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518470BDBM518470(US11124509, Compound 42)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518477BDBM518477(US11124509, Compound 49)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518460BDBM518460(US11124509, Compound 31)
Affinity DataIC50: 1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518447BDBM518447(US11124509, Compound 4)
Affinity DataIC50: 1.37E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 518446BDBM518446(US11124509, Compound 2)
Affinity DataIC50: 1.37E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent